Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 4, 2026, 3:38 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–15 of 15 matching trials from the live ClinicalTrials.gov search.
Active, not recruiting Phase 3 Interventional

Pediatric Patients Aged 4 to 11 Years With APDS

NCT05438407
Conditions
APDS
Interventions
Leniolisib
Drug
Lead sponsor
Pharming Technologies B.V.
Industry
Eligibility
4 Years to 11 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
4
States / cities
Los Angeles, California • Standford, California • Atlanta, Georgia + 1 more
Conditions
Hereditary Angioedema
Interventions
rhC1INH
Drug
Lead sponsor
Pharming Technologies B.V.
Industry
Eligibility
13 Years and older
Enrollment
152 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
Fairfax, Virginia
Conditions
Mitochondrial Diseases
Interventions
Napazimone
Drug
Lead sponsor
Pharming Technologies B.V.
Industry
Eligibility
18 Years and older
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Akron, Ohio
Conditions
Primary Mitochondrial Disease
Interventions
KL1333, Placebo
Drug
Lead sponsor
Pharming Technologies B.V.
Industry
Eligibility
18 Years and older
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
20
States / cities
Orange, California • San Diego, California • San Francisco, California + 15 more
Conditions
Confirmed Coronavirus Disease
Interventions
Ruconest
Drug
Lead sponsor
Pharming Technologies B.V.
Industry
Eligibility
18 Years to 85 Years
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
4
States / cities
Marlton, New Jersey • Mount Holly, New Jersey • Ridgewood, New Jersey + 1 more
Active, not recruiting Phase 3 Interventional

Pediatric Patients Aged 1 to 6 Years With APDS

NCT05693129
Conditions
APDS
Interventions
Leniolisib
Drug
Lead sponsor
Pharming Technologies B.V.
Industry
Eligibility
1 Year to 6 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
4
States / cities
Los Angeles, California • Bethesda, Maryland • Shaker Heights, Ohio + 1 more
Conditions
PIDs Linked to PI3K
Interventions
Leniolisib
Drug
Lead sponsor
Pharming Technologies B.V.
Industry
Eligibility
12 Years to 75 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
3
States / cities
Bethesda, Maryland • Burlington, Massachusetts • New York, New York
Conditions
Graft Rejection, Kidney Transplantation
Interventions
plasmapheresis and IVIG, recombinant C1 inhibitor
Procedure · Drug
Lead sponsor
Pharming Technologies B.V.
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Madison, Wisconsin
Active, not recruiting Phase 2 Interventional

Leniolisib for Immune Dysregulation in PIDs

NCT06549114
Conditions
Primary Immunodeficiency Disorders (PIDs)
Interventions
Leniolisib
Drug
Lead sponsor
Pharming Technologies B.V.
Industry
Eligibility
12 Years to 75 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
Hereditary Angioedema
Interventions
rhC1INH, Placebo (Saline)
Drug
Lead sponsor
Pharming Technologies B.V.
Industry
Eligibility
13 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
15
States / cities
Scottsdale, Arizona • Granada Hills, California • Los Angeles, California + 12 more
Conditions
Hereditary Angioedema
Interventions
rhC1INH
Drug
Lead sponsor
Pharming Technologies B.V.
Industry
Eligibility
2 Years to 13 Years
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
1
States / cities
Portland, Oregon
Conditions
Hereditary Angioedema
Interventions
Recombinant human C1 inhibitor, Placebo
Biological · Other
Lead sponsor
Pharming Technologies B.V.
Industry
Eligibility
13 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
4
States / cities
Tampa, Florida • St Louis, Missouri • Lake Oswego, Oregon
Conditions
Activated PI3Kdelta Syndrome (APDS); PASLI Disease
Interventions
CDZ173
Drug
Lead sponsor
Pharming Technologies B.V.
Industry
Eligibility
12 Years to 75 Years
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2025
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
Kidney Failure
Interventions
rhC1INH, Saline Solution
Drug · Other
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Madison, Wisconsin
Conditions
Common Variable Immunodeficiency (CVID)
Interventions
Leniolisib
Drug
Lead sponsor
Pharming Technologies B.V.
Industry
Eligibility
12 Years to 75 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
5
States / cities
Aurora, Colorado • Bethesda, Maryland • Burlington, Massachusetts + 2 more